Duloxetine
Product Images NDC 67046-691

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 67046-691). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

D3 (Duloxetine 30mg 691)

Label for Duloxetine Delayed-Release 30 mg capsules, bottle of 30, labeled by Contract Pharmacy Services-PA. The label includes barcode and storage information, noting each capsule contains 33.7 mg duloxetine hydrochloride USP equivalent to 30 mg duloxetine.*

FDA Label Image

D6 (Duloxetine 60mg 679)

Label for Duloxetine 60 mg capsules, quantity 30, labeled by Contract Pharmacy Services-PA. Includes barcodes, storage instructions, and mentions duloxetine hydrochloride content equivalent to 60 mg duloxetine. Additional information includes lot number, expiration date, and packaging location in Warrington, PA.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, showing its molecular framework with aromatic rings, an oxygen atom, sulfur-containing thiophene ring, and the hydrochloride salt form.*

FDA Label Image

Figure 1 (Duloxetine 02)

A graph showing the proportion of patients with relapse over time from randomization to relapse (days). It compares two treatments: Duloxetine and Placebo, with Duloxetine showing a lower relapse proportion over approximately 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph comparing the proportion of patients with relapse over time from randomization to relapse in days. Two treatments are shown: duloxetine and placebo. The duloxetine line shows a lower proportion of relapse compared to placebo through approximately 250 days, indicating delayed relapse for patients on duloxetine compared to placebo.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine Delayed-Release at 20 mg QD, 60 mg QD, 60 mg BID, and placebo. The graph shows higher patient improvement percentages with Duloxetine compared to placebo across various levels of pain improvement.*

FDA Label Image

Figure 4 (Duloxetine 05)

A cumulative percentage graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine Delayed-Release 60 mg BID compared to placebo. The graph plots three lines representing Duloxetine 60 mg BID (two sets) and placebo, illustrating greater patient improvement with Duloxetine over placebo across pain improvement percentages.*

FDA Label Image

Figure 7 (Duloxetine 06)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60/120 mg once daily versus placebo. The graph shows two lines with plotted points depicting patient improvement over a range of pain reduction percentages up to 100%.*

FDA Label Image

Figure 8 (Duloxetine 07)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two lines: one for Placebo and one for Duloxetine Delayed-Release (DUL) 60 mg once daily, illustrating the difference in patient improvement over a range of pain improvement percentages.*

FDA Label Image

Figure 9 (Duloxetine 08)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60/120 mg once daily and placebo. The graph shows two curves illustrating patient response across a range of pain improvement percentages from 0 to 100.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.